title: [Prognostic importance of selected molecular genetic immunohistochemical markers and DNA ploidy in endometrial cancer].
abstract: OBJECTIVE
  The aim of the study was the analysis of the new molecular genetic immunomarkers (p53, c-erbB-2, Ki 67, bcl-2) hormonal receptors (ER, PR) and ploidy disturbances and their relation to the most important prognostic factors for endometrial cancer.
  
  
  METHODS
  Prospective study.
  
  
  METHODS
  Dept. of Gynaecology and Obsterics, Laboratory of Experimental Medicine, Institute of Pathology, Institute of Molecular and Transplational Medicine, Medical Faculty and University Hospital, Olomouc.
  
  
  METHODS
  The study group consisted of 88 endometrial cancer patients. The biopsies of the tumours obtained at operations were routinely histopathologically examined. Subsequently, the immunohistochemical tumormarkers were determined. The same biopsies were examined by microdissection and flow cytometric ploidy analysis and karyotyping. The findings were compared with the most important prognostic factors for endometrial cancer, mainly with clinical stage of the disease, grade and histopathological type.
  
  
  RESULTS
  Aneuploidy was found in 71% in the group of poorly differentiated endometrial cancers (G3) in contrast to 47% in the group of G1 and G2 tumours. High expression of p53, Ki 67, c-erbB-2 and low rate of sex hormone receptors was found in the prognostically unfavourable group (G3).
  
  
  CONCLUSIONS
  Aneuploidy seems to be an important prognostical factor for endometrial cancer patients. Identification of p53, Ki 67, c-erbB-2, ER a PR is a useful tool to specify a group of prognostically unfavourable patients.
authors.affiliation: Porodnicko-gynekologická klinika LF UP a FN Olomouc. kudelam@fnol.cz
authors.forename: M
authors.initials: M
authors.lastname: Kudela
authors.forename: R
authors.initials: R
authors.lastname: Pilka
authors.forename: M
authors.initials: M
authors.lastname: Lubuský
authors.forename: P
authors.initials: P
authors.lastname: Hejtmánek
authors.forename: P
authors.initials: P
authors.lastname: Dzubák
authors.forename: S
authors.initials: S
authors.lastname: Brychtová
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis; D004273:DNA, Neoplasm / Q000235:genetics*; D016889:Endometrial Neoplasms / Q000235:genetics* / Q000473:pathology; D005260:Female; D005434:Flow Cytometry; D005819:Genetic Markers; D006801:Humans; D007150:Immunohistochemistry; D007621:Karyotyping; D019394:Ki-67 Antigen / Q000032:analysis / Q000235:genetics; D011003:Ploidies; D011379:Prognosis; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000032:analysis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D011960:Receptors, Estrogen / Q000235:genetics; D011980:Receptors, Progesterone / Q000032:analysis; D016159:Tumor Suppressor Protein p53 / Q000032:analysis
chemical_list: D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm; D005819:Genetic Markers; D019394:Ki-67 Antigen; D019253:Proto-Oncogene Proteins c-bcl-2; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D016159:Tumor Suppressor Protein p53